A priced round sells preferred shares at an agreed valuation now. A SAFE defers that valuation until a future priced round. The choice is not which is "better" — it is whether you need speed and opacity pre-traction, or can afford the legal cost and cap-table clarity of pricing today.
Reading time: 8 minutes. The worked example compares $3M on a $15M-cap SAFE stack vs a priced seed at $15M pre — ~20% vs ~16.7% dilution, plus docs and protective provisions.
A priced round is an equity financing: investors buy preferred shares at a negotiated price per share, based on a pre-money or post-money valuation you agree today. The cap table updates at closing. Everyone knows who owns what.
A SAFE or convertible note defers that reckoning. You take money now; ownership converts at the next priced round (or other trigger). Until conversion, SAFE holders are not on the cap table as shareholders — the dilution is real but opaque.
Priced rounds come with full documentation: term sheet, stock purchase agreement (SPA), investors' rights agreement (IRA), voting agreements, and often amended articles. In Europe, legal cost for a priced seed commonly runs €10k–30k+ and takes weeks. A standard YC SAFE round is often €500–2k per investor set and can close in days.
Priced preferred stock carries protective provisions — investor veto rights on major decisions (sale, new financing, charter changes). It sets liquidation preference (typically 1× non-participating at seed, but verify). It may grant board seats or observer rights. It triggers a 409A valuation update in the US context and affects how you report equity to future hires.
SAFEs defer most of that until conversion. You get cash and a short document. You do not get clarity on final ownership until the priced round — and if you stack multiple SAFEs at different caps, the modelling work lands on you (or your lawyer) later.
When founders price earlier: larger seed checks ($3M+), lead investors who require preferred stock, corporate governance needs, or a desire for a clean cap table before Series A. When founders stay on SAFEs: sub-$2–3M party rounds, fast closes, pre-product or pre-PMF stages where valuation is genuinely uncertain.
You raise $3M. Two structures:
SAFE stack (post-money SAFEs, all at $15M cap): total investor ownership at conversion = $3M ÷ $15M = 20.0% — locked regardless of how many investors split the $3M. Fast close, low legal cost, dilution known only if you model it. No board seat, no protective provisions, until conversion.
Priced seed at $15M pre-money, $3M new money: post-money = $18M. Investor ownership = $3M ÷ $18M = 16.7%. Higher legal cost, weeks of docs, but you know the % today. The investor likely holds preferred stock with protective provisions and possibly a board observer seat.
Same dollars, different dilution: the SAFE stack costs you ~3.3 percentage points more at conversion than the priced seed in this scenario — because post-money SAFE ownership is computed against the cap, not against pre-money plus new money. That gap is not hidden; it is just easy to miss when you are optimising for speed.
Tradeoff summary: SAFE = faster, cheaper, more dilutive in this example. Priced = slower, expensive, clearer governance, less dilutive today. Your stage and lead investor's requirements pick the winner — not a blog post.
Under ~$2–3M with angels and no lead demanding preferred stock: SAFEs are the default. $3M+ with an institutional lead who expects preferred: price the round. Forcing a SAFE on a lead who wants priced preferred wastes time.
Stacked SAFEs at different caps create a modelling project before every Series A conversation. If you are 12 months from Series A and the cap table is already complex, pricing now can be cheaper than converting four SAFEs under time pressure.
If you have €10k+ and 4–6 weeks, priced is viable. If you have €2k and need cash this month, SAFE. Do not start a priced round you cannot afford to finish — half-signed SPAs are worse than a clean SAFE.
Priced preferred comes with veto rights and information rights. That is appropriate when investors are large enough to earn it. It is overhead when you are still finding product-market fit and need to move fast.
Default for European pre-seed under $2M: post-money SAFE. Revisit pricing when check sizes, lead requirements, or Series A timing demand a cap table you can show without a spreadsheet caveats slide.
Upload the document. Prism classifies: SAFE, convertible note, or priced-equity package (SPA, IRA, term sheet). For SAFEs and notes, it extracts cap, discount, MFN, and maturity. For priced rounds, it extracts liquidation preference, protective provisions, board composition, and non-standard voting thresholds.
The output compares each term against your playbook — e.g. "1× non-participating only" or "no board seat below $1M check." A priced seed with participating preferred and full protective provisions triggers a different finding than a standard YC SAFE — because the risk profile is different, not because one is always wrong.
Instrument choice is a governance decision disguised as a paperwork decision. Prism makes the governance terms visible before you sign.
Closed alpha. Premium tier — €49/month, no free tier, no demos. Read the home page if you haven't, then drop your email.
SAFE vs convertible note — if you are not ready to price, the first fork is SAFE or note — not priced vs SAFE.
How a SAFE converts — the mechanics that turn deferred SAFE money into priced-round shares.
Startup dilution — how to compare 20% SAFE stack vs 16.7% priced in your fully-diluted model.
If there's a term you're trying to understand right now and it's not here, tell us — the order we write these in is driven by what founders ask for.
